secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276891
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q3 2022 XPOVIO sales up 20% YoY; net loss narrows to $0.45/share; guidance reaffirmed
--------------------------------------------------------------------------------

- Total revenue $36.1M (-4% YoY); XPOVIO net product revenue $32.0M (+20% YoY).
- Net loss $36.3M ($0.45 per share) vs $51.8M ($0.69) in Q3 2021; cash $150.1M.
- Reaffirmed FY2022 guidance: total revenue $155-165M, XPOVIO $120-130M.
- Initiated Phase 3 selinexor maintenance in TP53 wild-type endometrial cancer; topline 2024.
- Phase 1 selinexor+ruxolitinib in myelofibrosis shows SVR35 at 79% at week 12; updated data at ASH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/0001193125-22-276891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522276891/d403188d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer